The immunomodulation effects of small nuclear ribonucleoprotein polypeptide G (SNRPG) in human brain tumors

Abstract

Small nuclear ribonucleoprotein polypeptide G (SNRPG) or Smith protein G (SmG) is vitally involved in the biogenesis of the major and minor spliceosome precursors that are spliceosomaluridyl-rich small nuclear ribonucleoprotein particles (U snRNPs; U1, U2, U4 and U5). The plausible involvement of SNRPG in tumor formation and oncogenesis has made it the center of studies. In this study, for the first time, this tumorigenic and immune-modulating functioning of SNRPG employing TCGA and GEO dataset-derived brain tumors has been scrutinized by us. Most tumors demonstrate higher SNRPG expression compared with normal ones, including various human brain tumors. The TCGA cohorts also displayed variation in SNRPG genetic status in different tumor samples. Experimental validations supported the oncogenic effect of SNRPG, and furthermore, the mechanism might be associated with the regulation of immune response. Further bioinformatics analysis revealed that some malignancies demonstrated a link between the SNRPG expression and CD8 + T-cell while others were linked with fibroblast infiltration. Moreover, the mechanistic aspects of SNRPG entailed spliceosome-associated functions among others. More in-depth research indicated that SNRPG may impact tumorigenesis of human brain tumors via exerting post-transcriptional modulation of TP53 through the mechanism of alternative polyadenylation (APA) at the region of 3’ untranslated regions (UTRs). However, more research should be done to further confirm the preliminary results in our current study. Overall, current research presents the first detailed scrutiny of the oncogenic and immune-modulating functioning of SNRPG in several malignancies of human brain.